SIP
NAVB

Stoneridge Investment Partners’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Stoneridge Investment Partners’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-850
Closed -$27K – 313
2015
Q1 		$27K Hold
850
– – ﹤0.01% 265
2014
Q4 		$32K Buy
+850
New +$23.4K ﹤0.01% 252
2014
Q2 		– Sell
-6,901
Closed -$255K – 260
2014
Q1 		$255K Sell
6,901
-225
-3% -$8.53K 0.05% 171
2013
Q4 		$295K Buy
+7,126
New +$279K 0.06% 161

Other funds holding NAVB

PM
Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Stoneridge Investment Partners's NAVB Position: Q2 2015 in Review

Stoneridge Investment Partners sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2015, closing a stake of 850 shares — an estimated $27K sold.

Stoneridge Investment Partners first reported a position in NAVB in Q4 2013 and held it in 4 quarters. The position peaked at $295K in Q4 2013. 79 funds tracked by Wall St. Rank hold NAVB as of Q2 2015.

  • Stoneridge Investment Partners reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2015 after selling out during the quarter.
  • Stoneridge Investment Partners sold 850 Navidea Biopharmaceuticals Inc. shares in Q2 2015, an estimated $27K.
  • Stoneridge Investment Partners first reported a position in Navidea Biopharmaceuticals Inc. in Q4 2013 and held it in 4 quarters.
  • Stoneridge Investment Partners's Navidea Biopharmaceuticals Inc. position peaked at $295K in Q4 2013.
  • 79 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2015.

Based on Stoneridge Investment Partners's 13F filing for Q2 2015, filed 29 Jul 2015.